BANK VONTOBEL/PUT/ELI LILLY & CO/580/0.1/20.12.24 Share Price

Warrant

DE000VD21M50

Real-time Bid/Ask 09:02:46 01/07/2024 BST
0.29 EUR / 0.31 EUR -6.25% Intraday chart for BANK VONTOBEL/PUT/ELI LILLY & CO/580/0.1/20.12.24
Current month-57.89%
1 month-57.33%
Date Price Change
01/07/24 0.29 -9.38%
28/06/24 0.32 -5.88%
27/06/24 0.34 0.00%
26/06/24 0.34 0.00%
25/06/24 0.34 -5.56%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 07:44 am

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer Vontobel Vontobel
WKN VD21M5
ISINDE000VD21M50
Date issued 27/03/2024
Strike 580 $
Maturity 20/12/2024 (172 Days)
Parity 10 : 1
Emission price 1.28
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.02
Lowest since issue 0.29
Delta-0.03x
Omega 8.604
Premium36.3x
Gearing280.22x
Moneyness 0.6406
Difference Strike -325.4 $
Difference Strike %-56.10%
Spread 0.02
Spread %6.45%
Theoretical value 0.3000
Implied Volatility 39.07 %
Total Loss Probability 94.65 %
Intrinsic value 0.000000
Present value 0.3000
Break even 576.77 €
Theta-0.03x
Vega0.04x
Rho-0.01x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4 USD
Average target price
868.9 USD
Spread / Average Target
-4.03%
Consensus